Charles T Taylor1, Sonja Lyubomirsky2, Murray B Stein1. 1. Department of Psychiatry, University of California , San Diego, CA, USA. 2. Department of Psychology, University of California, Riverside, CA, USA.
Abstract
BACKGROUND: Research suggests that the positive affect system may be an important yet underexplored treatment target in anxiety and depression. Existing interventions primarily target the negative affect system, yielding modest effects on measures of positive emotions and associated outcomes (e.g., psychological well-being). The objective of the present pilot study was to evaluate the efficacy of a new transdiagnostic positive activity intervention (PAI) for anxiety and depression. METHOD: Twenty-nine treatment-seeking individuals presenting with clinically impairing symptoms of anxiety and/or depression were randomly allocated to a 10-session protocol comprised of PAIs previously shown in nonclinical samples to improve positive thinking, emotions, and behaviors (e.g., gratitude, acts of kindness, optimism; n = 16) or a waitlist (WL) condition (n = 13). Participants were assessed at pre- and posttreatment, as well as 3- and 6-month follow-up, on measures of positive and negative affect, symptoms, and psychological well-being. ClinicalTrials.gov Identifier: NCT02330627 RESULTS: The PAI group displayed significantly larger improvements in positive affect and psychological well-being from pre- to posttreatment compared to WL. Posttreatment and follow-up scores in the PAI group were comparable to general population norms. The PAI regimen also resulted in significantly larger reductions in negative affect, as well as anxiety and depression symptoms, compared to WL. Improvements across all outcomes were large in magnitude and maintained over a 6-month follow-up period. CONCLUSIONS: Targeting the positive affect system through a multicomponent PAI regimen may be beneficial for generating improvements in positive emotions and well-being, as well as reducing negative affect and symptoms, in individuals with clinically impairing anxiety or depression.
RCT Entities:
BACKGROUND: Research suggests that the positive affect system may be an important yet underexplored treatment target in anxiety and depression. Existing interventions primarily target the negative affect system, yielding modest effects on measures of positive emotions and associated outcomes (e.g., psychological well-being). The objective of the present pilot study was to evaluate the efficacy of a new transdiagnostic positive activity intervention (PAI) for anxiety and depression. METHOD: Twenty-nine treatment-seeking individuals presenting with clinically impairing symptoms of anxiety and/or depression were randomly allocated to a 10-session protocol comprised of PAIs previously shown in nonclinical samples to improve positive thinking, emotions, and behaviors (e.g., gratitude, acts of kindness, optimism; n = 16) or a waitlist (WL) condition (n = 13). Participants were assessed at pre- and posttreatment, as well as 3- and 6-month follow-up, on measures of positive and negative affect, symptoms, and psychological well-being. ClinicalTrials.gov Identifier: NCT02330627 RESULTS: The PAI group displayed significantly larger improvements in positive affect and psychological well-being from pre- to posttreatment compared to WL. Posttreatment and follow-up scores in the PAI group were comparable to general population norms. The PAI regimen also resulted in significantly larger reductions in negative affect, as well as anxiety and depression symptoms, compared to WL. Improvements across all outcomes were large in magnitude and maintained over a 6-month follow-up period. CONCLUSIONS: Targeting the positive affect system through a multicomponent PAI regimen may be beneficial for generating improvements in positive emotions and well-being, as well as reducing negative affect and symptoms, in individuals with clinically impairing anxiety or depression.
Authors: Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos Journal: Lancet Date: 2013-08-29 Impact factor: 79.321
Authors: Pim Cuijpers; Matthias Berking; Gerhard Andersson; Leanne Quigley; Annet Kleiboer; Keith S Dobson Journal: Can J Psychiatry Date: 2013-07 Impact factor: 4.356
Authors: Igor Elman; Steven Lowen; Blaise B Frederick; Won Chi; Lino Becerra; Roger K Pitman Journal: Biol Psychiatry Date: 2009-07-29 Impact factor: 12.810
Authors: Joep van Agteren; Matthew Iasiello; Laura Lo; Jonathan Bartholomaeus; Zoe Kopsaftis; Marissa Carey; Michael Kyrios Journal: Nat Hum Behav Date: 2021-04-19
Authors: Lorra Garey; Brooke Y Kauffman; Kara F Manning; Samar A Taha; Norman B Schmidt; Clayton Neighbors; Michael J Zvolensky Journal: J Addict Med Date: 2019 Jan/Feb Impact factor: 3.702
Authors: Thomas V Merluzzi; James E Pustejovsky; Errol J Philip; Stephanie J Sohl; Mark Berendsen; John M Salsman Journal: Psychooncology Date: 2019-07-09 Impact factor: 3.894
Authors: Kean J Hsu; Mary E McNamara; Jason Shumake; Rochelle A Stewart; Jocelyn Labrada; Alexandra Alario; Guadalupe D S Gonzalez; David M Schnyer; Christopher G Beevers Journal: Depress Anxiety Date: 2020-06-24 Impact factor: 6.505
Authors: Molly W Vaughan; Michael P LaValley; David T Felson; Gael I Orsmond; Jingbo Niu; Cora E Lewis; Neil A Segal; Michael C Nevitt; Julie J Keysor Journal: Arthritis Care Res (Hoboken) Date: 2018-02-18 Impact factor: 4.794
Authors: James D Doorley; Fallon R Goodman; David J Disabato; Todd B Kashdan; Jennifer S Weinstein; Alexander J Shackman Journal: Emotion Date: 2020-01-16